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The purpose of this NTIP user guide is to provide technical guidance in the use and 
interpretation of NTIP reports. 
None of the contents of this manual are intended to be specific guidance for tuberculosis 
medical practice, public health practice, program evaluation, or program management.  
However, NTIP is designed to be useful for workers in each of these areas. General knowledge 
in these areas is helpful for understanding NTIP and making optimal use of its reports, and this 
guide refers the user to national guidelines or policies that form the basis for the indicators and 
the interpretation of the reports in NTIP. 
 
For future updates of this User Guide, please access  
http://www.cdc.gov/tb/programs/evaluation/pdf/ntipuserguide.pdf
The National Tuberculosis Indicators Project (NTIP) Companion for Data Managers can be 
accessed at http://www.cdc.gov/tb/programs/evaluation/pdf/companionfordatamanagers.pdf
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ARPE: Aggregate Reports for Tuberculosis Program Evaluation (for contact investigations)
CDC: Centers for Disease Control and Prevention
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NAA:  Nucleic acid amplification
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NTIP: National Tuberculosis Indicators Project
NTSS: National Tuberculosis Surveillance System
RVCT: Report of Verified Case of Tuberculosis
TAT: Turnaround time
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Tuberculosis (TB) remains a public health threat and a major challenge in the United States. 
Operational research, monitoring, and evaluation are critical to help TB program managers find 
opportunities, understand barriers, and prioritize efforts for improving program effectiveness. 
In collaboration with local and state TB partners, the Division of Tuberculosis Elimination (DTBE) 
selected national TB program objectives and developed the National Tuberculosis Indicators 
Project (NTIP) to enhance capacity for monitoring and evaluating through standardized indicators 
and reports. NTIP, implemented in 2009, facilitates the use of nationally collected data to help 
program officials monitor progress.
The goal of NTIP is to help TB program officials and staff members —
 ■ Use data they have submitted for surveillance to report progress
 ■ Monitor achievements toward national objectives
 ■ Work with community partners and local program staff to inform decisions on program 
planning, evaluation, and resource allocation
National TB Indicators
The national TB program objectives reflect priorities for TB control in the United States. 
The five major programmatic activities (see Figure 1.1, Activities) are to —
 ■ Provide education and training to community providers
 ■ Find and treat active TB 
 ■ Investigate contacts 
 ■ Prevent TB in high risk populations
 ■ Monitor and evaluate interventions
Figure 1.1, Logic model for TB Elimination in the United States, illustrates the core functions 




































The national objectives, which are key outputs from these activities, were recommended by the 
National TB Objectives Workgroup as essential measurements of activities related to effective TB 
control and prevention. A comprehensive list of the national objectives and performance targets 
is included in Appendix A. 
For each national objective, a standardized indicator was developed to set program goals and 
measure progress. Using data that are routinely reported to the Centers for Disease Control and 
Prevention (CDC) through four different systems, NTIP monitors the indicators related to TB 
cases, contacts, and immigrants and refugees who arrived in the United States with TB Class 
B notification or are suspected of having TB disease. Objectives related to education, training, 
and program evaluation are not monitored in NTIP. Table 1.1 lists the national TB indicators (For 
more specific information about TB indicators and performance targets for 2020, see Appendix A.)
Historically, managers in TB programs have calculated their own performance indicators and 
reported progress to CDC. Variations in the calculations have hindered the ability to observe 
and compare performance between programs and to track progress nationwide. NTIP provides 
a standardized method for calculating indicators, assessing TB control efforts, and tracking 
progress within and across TB programs.
NTIP reports are based on de-identified surveillance data submitted to CDC; thus, they contain 
no personally identifiable information. The data sources include
 ■ National Tuberculosis Surveillance System (NTSS)
 ■ TB Genotyping Information Management System (TB GIMS)
 ■ Aggregate Reports for Tuberculosis Program Evaluation (ARPE)
 ■ Electronic Disease Notification (EDN) System 
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Table 1. List of national TB indicators included in NTIP
TB Incidence
 ■ TB Incidence Rate (Overall) 
 ■ U.S.-Born Persons
 ■ Foreign-Born Persons
 ■ U.S.-Born Non-Hispanic Blacks or African Americans
 ■ Children Younger than 5 Years of Age
Case Management and Treatment
 ■ Known HIV Status
 ■ Treatment Initiation
 ■ Recommended Initial Therapy
 ■ Sputum Culture Result Reported
 ■ Sputum Culture Conversion
 ■ Completion of Therapy
Laboratory Reporting
 ■ Laboratory Turnaround Time – Culture
 ■ Laboratory Turnaround Time – NAA
 ■ Drug-Susceptibility Results
 ■ Universal Genotyping
Contact Investigations
 ■ Contact Elicitation
 ■ Examination
 ■ Treatment Initiation
 ■ Treatment Completion
Examination of Immigrants and Refugees
 ■ Examination Initiation 
 ■ Examination Completion
 ■ Treatment Initiation
 ■ Treatment Completion
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Who can use NTIP? 
NTIP reports are provided to public health officials in TB programs. The reports are available for 
states and selected counties with high TB incidence. They are also available for specially defined 
geographic regions (e.g., publc health districts, health centers) at the requests of TB program 
officials. The personnel in TB programs do not have to do any additional work or collect any 
additional data to generate NTIP reports. Program personnel can only access reports for their own 
jurisdiction. Access to NTIP is authorized by state TB system administrators or local  
TB program officials.
Program managers can use NTIP reports to —
 ■ Monitor local progress toward achieving the national TB program objectives
 ■ Help conduct cohort reviews
 ■ Report progress under the terms of cooperative agreements
 ■ Set priorities for improvements and resource allocation
 ■ Validate data
 ■ Provide technical assistance to community partners and local programs
 ■ Provide outreach and training
CDC staff members use NTIP reports as a source of information when working with cooperative 
agreement recipients. This helps to select TB programs that might need additional technical 
assistance. Additionally, NTIP data are used to assess national progress toward achieving 
objectives and established performance targets.
The national performance targets are provided as guidance. Achieving the national performance 
targets will not be feasible in all settings. Managers in TB programs should work with their DTBE 
program consultants to set performance targets based on what is feasible for their setting.
Interpreting and Using NTIP Reports
Correct interpretation of NTIP reports is critical, and it requires understanding the context under 
which a specific TB program is operating. TB program managers and partners can use NTIP 
reports to facilitate discussions and generate questions, to solicit inputs, and to encourage 
problem-solving among staff members. While NTIP provides quantitative progress reports on the 
recommended objectives, program staff members who are intimately involved in the day-to-day 
operation of the program have the most specific information for providing insight and helping to 
interpret the reports in NTIP.
Indicator data for states or program areas with low TB incidence should be interpreted with 
caution since estimates for these program areas are sparse.
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While NTIP Workgroup strives to achieve high level of precision in the formulation of indicators, 
the accuracy of indicators are limited by surveillance data systems from which indicator data 
are derived. The quality of surveillance data and data definition affect the accuracy of indicator 
reported in NTIP. Limited data collected in the national surveillance system may prevent 
indicators from further analysis. In some indicators, exclusion criteria could not be incorporated 
in the calculation because of lack of data. 
NTIP reports should be used as a monitoring tool. TB program managers and staff are 
encouraged to conduct additional analysis when possible to provide insights for interpreting  
NTIP reports.  
Organization of This User Guide 
This user guide provides an overview of the NTIP system and the indicators. The purpose of this 
guide is to help the user in the interpretation of NTIP reports. None of the contents are intended 
to be specific guidance for tuberculosis medical practice, public health practice, program 
evaluation, or program management. However, NTIP is designed to be useful for workers in each 
of these areas. General knowledge in these areas is helpful for understanding NTIP and making 
optimal use of its reports, and this guide refers the user to national guidelines or policies that 
form the basis for the indicators and the interpretation of the reports in NTIP.
Chapters II, III, and IV outline step-by-step instructions on how to navigate and use the functions 
of the system. This includes how to generate NTIP reports and export line-listed data.
Chapters V to IX of this guide introduce indicators and reports related to TB incidence rates,  
and each of the key programmatic activities including case management and treatment, 
laboratory reporting, contact investigation, and the examination of immigrants and refugees. 
Detailed exploration of, and rationale for, the indicators and the public health significance of  
the objectives are discussed. Data sources and detailed calculations for each indicator are  
also provided. 
Logic models describing key activities, outputs, and the intended outcomes of TB control and 
prevention activities are included in some sections. Indicators that are measured in NTIP are 
highlighted in the logic models. These logic models can be used to select relationships between 
various program activities for further study.
Finally, Chapter X highlights how surveillance data quality (i.e., accuracy, completeness and 
promptness) could impact NTIP indicator reports. This chapter helps users understand how to 
use NTIP to assess surveillance data quality and identify data issues.        
Resources
CDC. National TB Program Objectives and Performance Targets  
http://www.cdc.gov/tb/programs/Evaluation/Indicators/default.htm
CDC. TB Program Evaluation Handbook  
http://www.cdc.gov/tb/programs/Evaluation/TBEvaluationHandbook_tagged.pdf
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II. NTIP System Overview
This chapter provides an overview of the NTIP system and discusses the NTIP user access policy, 
the login process, and how to find resources and references available in NTIP.
NTIP System
NTIP reports are available for use by federal, state, and local public health partners to monitor 
the effectiveness of TB prevention and control activities. Only authorized users have access to 
data that were reported by their respective public health jurisdictions.  Figure 2.1 illustrates the 
flow of data from state TB programs to national data reporting systems and finally to NTIP.
























Two types of data are shared in NTIP:
1. Indicator data  
Indicator data are calculated statistics presented in a report. The statistics are stratified 
by relevant characteristics and displayed in tables, charts, and graphs used to track 
performance trends. 
2. Line-listed data 
Line-listed data provide key data elements from the surveillance system that are used to 
calculate indicators. The line-listed data are only shared with authorized users from the 
respective reporting jurisdiction where data was reported. State, city, and county case 
numbers reported in the Report of Verified Case of Tuberculosis (RVCT) are provided in the 
line list to facilitate communication and help staff members in the reporting jurisdiction 
assess data issues and programmatic concerns. Personally identifiable information is not 
shared via the NTIP line list. The line-listed data are exportable in an Excel spreadsheet. 
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Data Security and Confidentiality
NTIP does not store or share any personally identifiable information on TB patients or individuals 
suspected of having TB disease or infection. No information is stored related to date of birth, date 
of TB diagnosis, date of test results, or date of treatment. 
Specific jurisdiction information, such as city, county, health districts, name of the public 
health center, strategic planning areas, and regions, may indirectly lead to the identification 
of individuals, particularly in geographic regions where TB is rare. This type of jurisdiction 
information is used in NTIP to provide local level reports.
To ensure confidentiality, CDC does not provide NTIP reports for jurisdictions reporting less than 
or equal to an average of 15 cases per year (based on counted cases from 2006 through 2008) 
without a formal request from TB program officials from the respective program. TB program 
officials can request reports for specific jurisdictions by sending an email to DTBESupport@cdc.gov.
User Access
NTIP reports and line-listed data are not available to, or accessible by, the public. Only 
authorized users from reporting jurisdictions have access to the data. Each state TB control 
official has designated a TB data system administrator(s) who is authorized to approve users in 
their jurisdiction for access to NTIP reports. Within a jurisdiction, various levels of access are 
available. A user can be granted access to reports for a specific geographic region, a public health 
jurisdiction, or a program area (see definition of program area on page 26). An administrator may 
also grant access to specific reports relevant to the roles and responsibilities of individual staff 
members. For example, an administrator may grant access to the Reports on the Examination 
of Immigrants and Refugees to staff members from Refugee Health without granting access to 
reports for other indicators. Likewise, an administrator may choose to limit line-list data access 
to the specific staff members responsible for ensuring the completeness and accuracy of data 
submitted to CDC. Users may be authorized access to the line list data for indicators calculated 
using data from the National TB Surveillance System (NTSS), or Electronic Disease Notification 
(EDN) system, or both.
Data Security on NTIP Server
Procedures developed by the CDC Office of the Chief Information Security Officer (OCISO) for 
authorizing, credentialing, and authenticating users ensure electronic data security. CDC’s Secure 
Access Management Services (SAMS) registers and authenticates all NTIP users. Information 
technology security procedures, as stipulated by OCISO, are in place to ensure that only 
authorized users will have access to surveillance data that were reported by their respective public 
health jurisdictions.
CDC is committed to maintaining strict confidentiality and security of the national surveillance 
information through the National TB Surveillance System (NTSS). NTIP is an extension of NTSS 
and is protected in the following ways:
 ■ Only authorized users who have accounts authenticated via CDC’s Secure Access 
Management Services (SAMS) and who are compliant with regulations of OCISO will be 
able to gain access to the system.
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 ■ NTIP data are housed on CDC servers protected by application firewalls to prevent 
unauthorized access.
 ■ TB control officials can customize user access to the data and information pertinent  
to individual staff members. 
 ■ TB data system administrators are given authority to grant access to staff members 
working in their jurisdictions. 
 ■ All potential users must be nominated by local TB data systems administrators and 
verified by CDC administrators.
 ■ No personally identifiable information is stored in NTIP.
Data Sharing Between States
Users will be granted access to data their programs have submitted for their jurisdictions only. 
Users will not be granted access to data or reports outside of their jurisdiction. 
Collaborations Between States 
CDC encourages staff members in various TB programs within a state, and among different 
states, to collaborate and share lessons learned.  A specific NTIP report type that enables users 
to present their data along with other programs’ data for use during regional meetings has been 
developed. Program officials who wish to participate in this should contact the DTBE Helpdesk, 
DTBESupport@cdc.gov, for assistance.
Access for Partners in TB Control 
For public health purposes, TB data systems administrators may authorize staff members from 
other health agencies (i.e., Refugee Health and State Public Health Laboratories) within their 
jurisdiction to access data for their jurisdiction. Administrators may choose to limit access for the 
staff members in these agencies to the reports and data pertinent to their work.
Use of NTIP Data 
Local and state TB program staff members are encouraged to share data reported in NTIP with 
other agencies and partner organizations. The reports and tabulations in NTIP are transferrable 
and can be copied to documents, reports, and presentation slides for sharing with community 
partners to inform programs serving the community. To ensure that the most current data are 
made available through NTIP, data submitted to CDC are imported weekly and used to calculate 
and generate NTIP reports. Data managers from reporting jurisdictions should, therefore, verify 
that all data reported to CDC are current and accurate.
18
Login Window 
NTIP system login is managed through the Secure Access Management Services (SAMS). Users 
must obtain a SAMS account prior to logging into NTIP. The NTIP Helpdesk will help users 
establish a SAMS account once the request and authorization for NTIP has been received from 
the designated TB systems administrator for the respective TB programs. 
Users can attempt to login to the system 3 times. If login is unsuccessful after 3 attempts, users 
will have to wait 1 hour before attempting to log into the system again. The password can be 
reset by clicking the “Forgot SAMS password?” link.
Below, is a screenshot of the SAMS homepage. 
A URL: Type https://sams.cdc.gov to access the NTIP system through CDC’s Secure Access 




B SAMS Credentials: This field provides the Login Options to enter a Username and Password. 
The Username is the user’s email address. This password is case sensitive. It must have eight 
or more characters, must not contain Username, must not have been used for SAMS during the 
previous 12 months, and must contain at least one each of the following: 
 ■ Letters (uppercase or lowercase) 
 ■ Numbers 
 ■ Special characters or symbols (such as # , @, or %) 
C SAMS Grid Card Credentials: shows the login option to use the Grid Card Credentials.
D HHS PIV Card: shows the login option for the HHS PIV Card. CDC users can login to the 
system using their government-issued identification card.  
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SAMS Menu 
Once logged into the Secure Access Management Services (SAMS) account, a user can access all 
TB systems for which he or she has been authorized through the SAMS Menu.
The screenshot below is an example of the SAMS Menu for a user who has been authorized 
access for NTIP and NTSS.
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NTIP Terms of Use
A  Terms of Use: Users must accept the Terms of Use in order to access the NTIP application.
A
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NTIP Menu and Announcement
A  NTIP Menu: This main menu provides user access to key NTIP functions: Reports, Line List, 
ARPE, and the Help/Resources section. Links to the Line List and ARPE are displayed on this 
menu only for users who have been granted access by their State TB Systems Administrator. 
B  Announcements: This field is used to communicate general information to NTIP users. 




Contact Us and Accessibility Assistance
Users can contact the NTIP Helpdesk for assistance by filling out an online form. Users can 
describe problems, provide comments, and attach a screen shot or a document to the form.




The Help/Resources section contains reference documents on NTIP and can be accessed from 
the main menu: 
Users can learn about various functions and features of NTIP and how to navigate the system.
Reference documents such as NTIP Workgroup meeting minutes, decision memos on changes to 
NTIP indicators, and calculations are archived in this section. This section is updated three to 
fours times a year. 
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III. Generating NTIP Reports
This chapter discusses the reporting function of NTIP. Users will learn how to generate and 
review various types of reports available in NTIP.  
Reports 
NTIP provides standardized methods for calculating indicators and tracking program progress 
toward national TB program objectives. Reports are available for all TB programs funded by CDC 
TB cooperative agreement as well as local jurisdictions as requested by the TB program officials 







A Report Settings: This main control panel allows users to generate NTIP reports.
B Data Source: Both current and frozen surveillance datasets are available for generating NTIP 
reports. As data are transmitted to CDC, they are updated in NTIP weekly under “Current Data.” 
Frozen datasets are snapshots of the NTSS database. It includes manual corrections to the data 
that could not be transmitted to CDC, and is created annually and made available on NTIP as 
soon as it is finalized, usually by early summer of the following year. Both current and frozen 
datasets include data from the National Tuberculosis Surveillance System (NTSS), Aggregate 
Reports for Tuberculosis Program Evaluation (ARPE) for Contact Investigations, and the 
Electronic Disease Notification (EDN) System. 
C Program Area: A Program Area in the NTIP system is a geographic region for which an NTIP 
report is available. A Program Area can be a state or a city that is funded by the CDC cooperative 
agreement or a local jurisdiction. Users can also select ‘United States’ as a Program Area to 
generate a national summary report. 
D Indicator: An indicator report is available for each national objective. The reports for Contact 
Investigation and Examination of Immigrants and Refugees contain a set of four indicators, 
and the report for Laboratory Turnaround Time contains a set of two indicators. A summary of 
indicators can be found in reports titled ‘Performance Snapshot’ or ‘Indicator Summary.’ 
E Case Year or Quarter: NTIP contains data from 2000 to present. The Date Counted is used to 
determine the cohort year for each case. Users can choose to see an annual or quarterly trend 
[Q1 (January–March), Q2 (April–June), Q3 (July–September), Q4 (October–December)]. With 
the exception of the reports for TB Incidence Rates and Contact Investigation, all reports are 
available in both yearly and quarterly trend. The trend is either 5 years or 5 quarters, ending 




F Report List: Once the first NTIP report is generated for view, users can modify reporting 
functions using this secondary control panel. Users can add additional reports to the list of 
reports or modify the parameters of reports. Users can print all the reports at once through  
this function.
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To generate a report,
1. Select “Reports” from the NTIP Menu.   
2. In the Data Source, Current Data field, select “(change)” data source. 
Select a Data Source.
3. Select a Program Area.
4. Select an Indicator to “view” or multiple indicators for “print.”
Note: 
 ■ Multi-report selection is only available for printing.
 ■ Funding Formula Variable Snapshot report is available for CDC TB cooperative agreement 
reporting jurisdictions only. Select “Frozen dataset” as the data source to view or print  
the report. 
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5. Select a Case Year or Quarter.
6. Select “Print” or “View” report (s). 
30
Indicator Reports
Indicator reports track a program’s performance over time for each objective and indicator.  
The report includes a trend graph, methods, data sources, and stratifications.  An example of 
page 1 for the Completion of Therapy indicator report is pictured below:
A Data updated: Date when the last data transmission was received at CDC from a reporting 
jurisdiction.
B National objective: The specific objective for which results are shown in the indicator report.
C Trend graph: The main graph in NTIP that tracks indicator trends. The graph includes a 5-year 







D Data table: The table provides the raw data (total eligible patients in the cohort period) used 
to calculate the indicator. 
E Methods: The method section provides a description of the indicator, the sources from which 
data are derived, the inclusion and exclusion criteria for the cohort of cases, and the calculation 
for the indicator.
F Analytic graphs: The graphs provide additional analyses for the indicator. An example of page 




A Color bar graph: The bar color indicates the completeness of data for the corresponding 
indicator. The color of the bar changes from purple to blue when the data reaches 90% 
completeness (for a detailed explanation, see Using NTIP Graphs to Assess Surveillance 
Data Quality and Promptness on page 126.) For the Completion of Therapy indicator, the 
completeness of the variable “Date Therapy Stopped” is used to determine data completeness. 
For the Known HIV Status Indicator report, the color of the trend graph changes when the 
completeness of the “HIV Status” variable reaches 90%. For the Drug Susceptibility Testing 
Indicator report, the completeness of the “Initial Drug Susceptibility Results” is used to 
determine when the bar graph turns from purple to blue. The percent completeness of these key 
variables used in NTIP can be found in the data completeness report titled “Data Reporting: 
RVCT.” 
B Cohort period: The cohort period spans 5 intervals. The interval can be year (for example, 
2009 through 2013) or quarter (for example, 2010-Q4, 2011-Q1, 2011-Q2, 2011-Q3, 2011-Q4). 
C  Program target: Program targets are established by managers at TB programs on the basis of 










D State average: State average is only shown in the reports for local jurisdictions under a state 
TB program such as  county or city health departments, regions, and health centers. For local 
jurisdictions reporting to a county or city TB program, the state average reflects the indicator for 
the county or city TB program.  
E National average: The national average reflects the overall trend in the indicator for the 
United States. 
F National target: The national targets are overarching targets for the United States. These 
targets were established based on the performance of the top 90th percentile state TB program 
that reported more than 150 cases from 2011–2013. The targets are based on a statistical 
model representing the 90th percentile values in the latest year estimated from a quantile 
regression on 2000–2013 data.
G Denominator (N): The number of cases in the cohort that meet the eligibility criteria for  
the objective.
H Numerator (n): The number of cases meeting the criteria for the objective. 
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Data Completeness Report 
The Data Completeness Report  provides the percentage of data completeness for key variables 
used in NTIP indicator calculations. A separate report is provided for RVCT, ARPE, and EDN. The 
RVCT Data Reporting provides the percentage of data completeness for key RVCT variables. This 
report is available by year or quarter. 
A Variable: Selected key variables used in indicator calculations are presented.
B RVCT fields (old/current): The corresponding RVCT field numbers are indicated on this list. 
The first number reflects those on the RVCT form prior to the 2009 revision. The second number 
refers to the field numbers on the current RVCT form. 
A B C
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C Completeness of variables: Percent completeness of variables reported in the RVCT. The 
completeness of variables such as “HIV Status,” “Initial Drug Susceptibility Result,” and “Date 
Therapy Stopped” are used as markers for the completeness of data for each indicator report. 
More detailed explanation of this reference can be found on page 32, under Color Bar Graph.
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Performance Snapshot & Indicator Summary
The Performance Snapshot and Indicator Summary reports provide a summary for all NTIP 
indicators. The Performance Snapshot report includes data for a selected year. The report 
presents both national and program targets for 2015 and the targets for the cohort period for 
which the report is generated (cohort year 2010 in the Performance Snapshot example below).
A Results: Performance results for each indicator. 
B N: The denominator for the respective indicator.
C n: The numerator for the respective indicator.
A B C
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In contrast to the Performance Snapshot, the Indicator Summary report (example below) 




IV. Exporting NTIP Line-Listed Data
This chapter outlines the steps for exporting line-listed data and the various data elements in a 
line list spreadsheet. For clarity, the line list spreadsheets are color-coded in this user guide. The 
actual line list spreadsheets exported from NTIP do not display any color.
The line list function provides a listing of cases, the RVCT fields and values from which data are 
derived, and their status with respect to NTIP indicators. The list allows users to see which cases 
are represented in the aggregated indicator reports. This helps users pinpoint specific cases that 
affected an indicator. The list can also be used to pinpoint the reason for data discrepancies 
between local program data and data received by CDC and can aid in the examination of a cohort 
of cases. 
Line-listed data are also available for the Examination of Immigrants and Refugees indicators, 
which are calculated using data from the EDN System.
Line-listed data are shared with authorized users from the reporting jurisdiction where data were 
reported. Access to line-listed data is granted by the designated state TB systems administrator 
for the respective user in the TB program. Once approved, requests can be submitted to the NTIP 
Helpdesk for processing. Users may be granted access to NTSS-based or EDN-based line-listed 
data, or both.   
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Export Line List Menu
A Data Source: Current and frozen dataset are available for generating reports. 
B Data System: National TB Surveillance System and Electronic Disease Notification Systems 
are two key data sources for NTIP indicators.
C Program Area: The Program Area corresponds to the Program Area in the Generate Report 
section. 
D Quarters: Line lists are available by quarters for year 2006 and forward. To export a line list 
for a whole year, select 4 quarters (e.g., 2008-Q1, 2008-Q2, 2008-Q3 and 2008-Q4).  
E Indicators: Selection for the indicators corresponds to the Indicator Reports section. Users 
can export a line list to coincide with the indicator report of interest or export a line list that 
includes multiple indicators. 
NOTE: To examine a cohort of cases for their status on each indicator, select and “Add” all 







To export a Line List,
1. Select “Line List” from the NTIP Menu.   
2. On the Export Line List Menu (shown on page 40), in the Data Source drop-down menu, 
select a dataset (e.g., Current Data or Frozen 2014 Dataset).
3. In the Data System option, select the system from which the indicator(s) of interest is 
calculated.  
4. In the Program Area field, select  the Program Area of interest. Click “Add.”
5. Select and “Add” the quarter(s) of interest under Quarters. To export a line list for a 
complete year, select all 4 quarters for that year.




A Case information details: Basic variables for matching case records to local TB registry. 
B Case Local ID and Latest Update Date: A unique identifier for each case with data submitted 
to CDC and the most recent date that data were received at CDC. 
C Data for selected variables used in NTIP calculation: Data used to determine whether a case 
meets the cohort eligibility criteria and the objective for the selected indicator(s) of interest.  
For example, in the ‘Reason Therapy Stopped’ column, users would see one of the eight RVCT 
responses for this variable such as completed therapy, lost, uncooperative or refused, adverse 
treatment event, not TB, died, other, or unknown. Users would be able to determine whether the 
data in this variable is the reason case was included or excluded from the completion of therapy 
indicator.
D Status toward meeting objective(s): Data denote whether a case is included or excluded in 
the analytic cohort, and if it is included, whether it is classified as having met the objective. For 
example, a patient who was dead at diagnosis will be denoted in the “Completion of treatment 
cohort” with an “N” for not being included in the analytical cohort for the Completion of Therapy 
indicator. Since this case is not included in the analytical cohort for this indicator, the data field 
for this case under the “Completion of treatment objective met” will be left blank.
E Variable description: Description of each variable.  




F RVCT field number(s): The RVCT field number associated with each variable or from which the 
variable was derived. If the variable is created from other variables, this is indicated by the word 
“created.”
G Variable name: Variable name used by DTBE.
Case Information Details
A Other Report Region: Program area(s) in which a single case may be recognized.  These 
regions may include county, city, or jurisdiction(s) for which NTIP reports are available. An 
abbreviated two- or three-letter code is used to indicate the regions. (Please contact the 
Helpdesk for assistance if needed.)
B State: State where the case was reported.
C Year (or Cohort Period): Date used to determine the cohort period for the case. Line lists are 
available by quarter (e.g., 2009-Q1, 2009-Q2, 2009-Q3, and 2009-Q4). To export a line list for 
a complete year, select all 4 quarters for that year. 
D Month-year Reported: The month and year when the case was reported. This variable can help 
with organization and review of cases. 
E State Case Number: State-specific case numbers provided to help users match records to 
those in the local TB registry.
F City/County Case Number: City/County case number is a unique number that is provided and 
used by local TB programs to match to the local TB registry. 
A B C D E F
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Case Local ID and Latest Update Date
A Case Local ID: A unique computer generated code for each case with data submitted to CDC. 
This identifier can be used to find duplicate records in NTSS. 
B Latest Update Date: The date when data was last received at CDC for the respective record.
A B
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Example of how to use the Exported Line List to determine patients  
for whom a particular objective was not met 
Background
The Export Line List option in NTIP will produce a list of cases for the Program Area and the 
time period of interest. The line list can be examined to see which cases contributed to meeting 
a specific objective and which cases did not. Below are instructions for how to conduct this 
examination. We will use the Completion of Therapy objective in this example. 
1. Within NTIP, follow the steps in Chapter IV, Exporting NTIP Line-Listed Data, to select the 
Program Area, the cohort period of interest, and the indicator for Completion of Therapy, and 
export the line list.
2. Click “Run.”
3. This downloads and exports your selected line list to a spreadsheet that you can open or save 
to your computer. In this example, we will open the line list in Excel.
4. Once you open the exported line list, you can use Excel functions to examine the 
information. We will show how to find cases for which treatment was incomplete according 
to the definition for this objective.
5. Click the column header for “Completion of treatment cohort” and the column header for 
“Completion of treatment objective met.” After both columns are highlighted, click “Sort & 
Filter” from the Excel menu, and select “Filter.” 
6. Click on the downward arrow at the bottom of the column header for “Completion of 
treatment cohort.”
7. In the bottom of the sort & filter box, uncheck the selection for “N” (this instructs Excel to 
not show cases that did not meet the cohort eligibility criteria). Click “OK.”
8. Click the downward arrow at the bottom of the column header for “Completion of treatment 
objective met.”
9. Uncheck the selection for “Y” (this instructs Excel to show cases that did not meet the 
objective for Completion of Therapy). Click “OK.”
10. You should now have a list of cases that met the eligibility criteria to be counted under the 
Completion of Therapy objective but did not meet the objective.
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Exported Line List
A Sort & Filter: Excel’s “Sort & Filter” function allows users to filter for cases that fit specific 
criteria; for example, you can sort those that meet the cohort eligibility criteria for an indicator. 
After you select a filter, the spreadsheet shows only those cases that meet the selected filter 
criteria.  
B Analytic cohort for a specific indicator: An analytic cohort consists of those cases that 
meet the eligibility criteria for the objective. “Y”= Yes, the case met the cohort definition and 
is eligible to meet the objective (for example,  patients who according to standard treatment 
guidelines should be able to complete treatment within 12 months). “N” = No, the case did not 
meet the cohort definition and is not included in the calculation of the objective.
C Indicator objective met: This variable indicates whether the case met the objective. “Y”= Yes, 
the case met the objective; “N”= No, the case did not meet the objective (for example, whether 
or not a patient completed treatment within 12 months). Fields left “blank” indicate the variable 
does not apply to the case.
D Selected variables (highlighted in purple): Data on key variables that are used to determine 
whether a case met the cohort eligibility criteria and the objective.





V. Monitoring Progress on Reducing TB Incidence
This chapter covers indicators that are related to TB incidence rates. 
Indicators for TB Elimination - Incidence Rates
 ■ TB Incidence Rate (Overall)
 ■ U.S.-Born Persons
 ■ Foreign-Born Persons
 ■ U.S.-Born Non-Hispanic Blacks or African Americans
 ■ Children Younger than 5 Years of Age
Data on TB cases are collected in the RVCT form and reported to CDC through the National TB 
Surveillance System (NTSS). All TB cases included in this set of indicators have been counted 
by reporting jurisdictions and meet the CDC TB surveillance definition and case verification 
criteria. (For tuberculosis case definition and recommendations for reporting and counting 
tuberculosis cases, please refer to Appendices A and B in the CDC Tuberculosis Surveillance 
Data Training, Report of Verified Case of Tuberculosis (RVCT): Instruction Manual, June 2009.  
Updates on surveillance definitions can also be found in the most recent publication of Reported 
Tuberculosis in the United States.
The United States Census Bureau’s Population Estimates are used to calculate overall TB 
incidence rates. American Community Survey population data are used to calculate rates for the 
sub-populations. Incidence rate reports are available in the yearly trend for states and selected 
cities receiving direct CDC funding only.
This set of indicators contributes to TB elimination by measuring incidence rates in groups for 
whom TB incidence is high. While not all four incidence rates are relevant to all settings in the 
United States, these four incidence rates represent major disparities between various population 
groups nationally. For some TB programs, incidence rates for different sub-populations may be 
more important to monitor. 
Resources
Treatment of Tuberculosis, MMWR 2003; 52 (No. RR-11)  
http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf
CDC Tuberculosis Surveillance Data Training, Report of Verified Case of Tuberculosis (RVCT): 
Instruction Manual, June 2009.  Appendices A and B.  
http://www.cdc.gov/tb/programs/rvct/InstructionManual.pdf
CDC. Reported Tuberculosis in the United States, 2013.  Appendices A and B.  
http://www.cdc.gov/tb/statistics/reports/2013/default.htm
American Community Survey 
http://www.census.gov/acs/www
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TB Incidence Rate (Overall)
National Objective: Reduce the incidence of TB disease
Indicator
Number of TB cases per 100,000 per year
CALCULATION
Cases Per 100,000 n/N
Numerator (n) Number of verified counted TB cases
Denominator (N) Population in the Program Area and year of interest
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DATA SOURCES 
 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) 
 ■ U.S. Census Bureau
• Population Estimates
or
• American Community Survey (ACS)
Note: Both Census’s Population Estimates and ACS provide similar estimates for the  
overall population. 
The TB incidence rate measures the burden of TB disease in a designated population. It provides 
a way for public health officials to assess the long-term outcome of TB prevention and control 
efforts and disease transmission.  The TB incidence rate has steadily decreased in the United 
States since 1993. A substantial increase in TB incidence rate would therefore merit close 
investigation to determine the cause and to implement interventions. Conversely, a larger than 
expected decrease warrants investigation to determine whether it represents a true decrease or a 
gap in case detection, surveillance, or notification.
Calculating the annual incidence rate enables program officials to track progress against previous 
years. Case stratifications may help identify communities or jurisdictions that require additional 
attention. These data also help support policy decisions and requests for funding. 
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U.S.-Born Persons
National Objective: Decrease the incidence of TB disease among U.S.-born persons
Indicator
Number of TB cases in U.S.-born persons per 100,000 per year
CALCULATION
Cases Per 100,000 n/N
Numerator (n) Number of verified TB cases in U.S.-born persons
Denominator (N) Population of U.S.-born persons in the Program Area and year  
of interest
(Quarterly report NOT available)
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DATA SOURCES
 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) field:
 – 12 (Country of Birth)
 – 12 (Country of birth: Specify) 
 ■ U.S. Census Bureau
• American Community Survey 
Note: Patients born in the U.S. territories and affiliated islands are reported as U.S-born.
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Foreign-Born Persons
National Objective: Decrease the incidence of TB disease among for foreign-born persons
Indicator
Number of TB cases in foreign-born persons per 100,000 per year
CALCULATION
Cases Per 100,000 n/N
Numerator (n) Number of verified counted TB cases in foreign-born persons
Denominator (N) Population of foreign-born persons in the Program Area and year  
of interest
(Quarterly report NOT available)
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DATA SOURCES
 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) field: 
 – 12 (Country of Birth) 
 – 12 (Country of birth: Specify)
 ■ U.S. Census Bureau
• American Community Survey
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U.S.-Born Non-Hispanic Blacks or African Americans
National Objective: Decrease the incidence of TB disease among U.S.-born non-Hispanic blacks  
or African Americans
Indicator
Number of TB cases in U.S.-born non-Hispanic blacks or African Americans per 100,000 per year
CALCULATION
Cases Per 100,000 n/N
Numerator (n) Number of verified counted TB cases in U.S.-born non-Hispanic blacks 
or African Americans
Denominator (N) Population of U.S.-born non-Hispanic blacks or African Americans in 
the Program Area and year of interest
(Quarterly report NOT available)
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DATA SOURCES 
 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) fields:
 – 10 (Ethnicity)
 – 11 (Race)
 – 12 (Country of Birth)
 – 12 (Country of birth: Specify)
 ■ U.S. Census Bureau
• American Community Survey 
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Children Younger than 5 Years of Age
National Objective: Decrease the incidence of TB disease among children younger than 5 years 
of age
Indicator
Number of TB cases in children younger than 5 years of age per 100,000 per year 
CALCULATION
Cases Per 100,000 n/N
Numerator (n) Number of verified counted TB cases in children younger than 5 years 
of age
Denominator (N) Population of children younger than 5 years of age in the Program Area 
and year of interest
(Quarterly report NOT available)
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DATA SOURCES 
 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) fields:
 – 1 (Date Reported) 
 – 8 (Date of Birth) 
 ■ U.S. Census Bureau
• American Community Survey
This indicator measures the incidence of TB disease in young children.
It has additional epidemiological implications because TB disease in young children 
reflects transmission of M. tuberculosis within the narrow interval of their lives (i.e., “recent 
transmission”), and it might represent missed public health opportunities to prevent cases. 
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VI. Monitoring Progress on Case Management and Treatment
This chapter covers indicators that are related to the case management and treatment of patients 
diagnosed with TB disease.
Indicators for Case Management and Treatment
 ■ Known HIV Status
 ■ Treatment Initiation
 ■ Recommended Initial Therapy
 ■ Sputum Culture Result Reported
 ■ Sputum Culture Conversion
 ■ Completion of Therapy
Data on TB cases are collected on the Report of Verified Case of Tuberculosis (RVCT) and 
reported to CDC through the National TB Surveillance System (NTSS). 
All TB cases included for this set of indicators have been counted by reporting jurisdictions and 
meet the CDC TB surveillance definition and case verification criteria. (For tuberculosis case 
definition and recommendations for reporting and counting tuberculosis cases, please refer to 
Appendices A and B in the CDC Tuberculosis Surveillance Data Training, Report of Verified Case 
of Tuberculosis (RVCT): Instruction Manual, June 2009.  Updates on surveillance definitions can 
also be found in the most recent publication of Reported Tuberculosis in the United States.) 
This set of indicators contributes to program evaluation by tracking key outputs of TB case 
management and treatment processes. The public health concept is that TB transmission 
and eventually incidence can be reduced through prompt initiation of treatment coupled with 
monitoring to ensure treatment effectiveness and adherence. Figure 3.1 is a logic model 
that outlines the activities, outputs, and the desired outcomes of TB prevention through case 
management and treatment of active TB cases.
Resources
Treatment of Tuberculosis, MMWR 2003; 52 (No. RR-11)  
http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf
CDC Tuberculosis Surveillance Data Training, Report of Verified Case of Tuberculosis (RVCT): 
Instruction Manual, June 2009  
http://www.cdc.gov/tb/programs/rvct/InstructionManual.pdf































































Known HIV Status 
National Objective: Increase the proportion of TB patients who have a positive or negative HIV 
test result reported
Indicator
Percent of TB patients with HIV test result reported as positive or negative
CALCULATION
Percent (%) n/N x 100
Numerator (n) Number of TB patients with HIV test result reported as positive  
or negative





 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) field:
 – 15 (Status at TB Diagnosis)
 – 26 (HIV Status at Time of Diagnosis)
This indicator measures how many cases reported in the RVCT include an HIV test result, which 
reflects the extent to which the the guidance for testing all TB patients for HIV infection and 
reporting is being followed.
U.S. guidelines stipulate that all TB patients should be tested for HIV and have the results 
reported with other TB surveillance findings. TB patients who have HIV infection require special 
considerations for medical care. This indicator shows whether HIV testing is being offered and 
the results are being reported.
The trend graph on this indicator provides an estimated proportion of TB-HIV co-infection in the 
Program Area of interest, as well as the percentage of TB patients with known HIV test results at 
the time of TB diagnosis. The data quality of this indicator is assessed using the completeness of 
“HIV Status” variable. The bar graph changes from purple to blue when the completeness of this 
variable reaches 90%. 
‘HIV Test Results and Reasons HIV Status Not Determined for TB Patients’ is a list of 
standardized reasons why HIV results are not known. 
(Quarterly report available)
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HIV tests may not be offered for many reasons. The graph below, ‘HIV Test Results and Reasons 
HIV Status Not Determined for TB Patients, by Age Group,’ allows program staff members to look 





National objective: For TB patients with positive acid-fast bacillus (AFB) sputum-smear results, 
increase the proportion who initiated treatment within 7 days of specimen collection
Indicator
Percent of TB patients with positive AFB sputum-smear result who initiated treatment within 7 
days of specimen collection
CALCULATION
Percent (%) n/N x 100
Numerator (n) Number of TB patients who initiated treatment within 7 days of 
specimen collection
Denominator (N) Number of TB patients with positive AFB sputum-smear results, alive 




 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) fields:
 – 15 (Status at TB Diagnosis)
 – 17 (Sputum Smear-Date Collected)
 – 36 (Date Therapy Started)
 – 37 (Initial Drug Regimen)
This indicator measures the promptness of initiating treatment for the patients who are more 
likely to be infectious — those who have AFB found on sputum-smear microscopy. 
This indicator was recommended by the working group because prompt TB diagnosis and 
treatment for patients who have AFB found on sputum-smear microscopy are both feasible and 
urgent, in keeping with national guidelines for medical care, program operations, and infection 
control. This indicator gives a summary overview of several interrelated activies which routinely 
could be assessed through reviews of cases and the cohort, and it is not a substitute for those 
types of review.
‘Treatment Initiation within 7 Days of Specimen Collection for TB Patients with Positive AFB 
Sputum-smear Results, by Provider Type’ allows program staff to observe differences, depending 





National objective: For patients whose diagnosis is likely to be TB disease, increase the 
proportion who are started on the recommended initial 4-drug regimen
Indicator
Percent of TB patients with initial drug regimen reported who are started on the recommended 
initial 4-drug regimen
CALCULATION
Percent (%) n/N x 100
Numerator (n) Number of TB patients who are started on the recommended initial         
4-drug regimen
Denominator (N) Number of TB patients with initial drug regimen reported, alive at 




 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) fields:
 – 15 (Status at TB Diagnosis)
 – 37 (Initial Drug Regimen)
This indicator measures the proportion of TB patients started on treatment with the four-drug 
regimen including isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB).
Because of isoniazid-resistant tuberculosis, guidance in the United States calls for a four-drug 
regimen including INH, RIF, PZA, and EMB for the initial phase of TB treatment for patients 
whose drug susceptibility results are unknown at the time treatment is started. 
The variable ‘initial drug regimen’ used in the indicator calculation consists of all drugs 
prescribed or taken in the first 2 weeks of treatment.  
Rifabutin is accepted as an alternative drug to rifampin for the recommended initial drug 
regimen for all TB patients. Another drug, rifapentine is acceptable for use among HIV co-
infected patients in the continuation phase of the treatment, but it is not recommended for use 
during initial therapy. Please refer to Treatment of Tuberculosis guidelines for details. 
TB programs are encouraged to monitor this indicator by provider type to determine which 
providers may not be adhering to the treatment recommendations.
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(Quarterly report available)
In some instances, PZA may be withheld for patients with special conditions such as liver 
disease, gout, or pregnancy.  However, these cases cannot be recognized specifically in the 
national surveillance system because of the lack of data collected on these conditions in the 
RVCT form, and therefore they cannot be excluded from the cohort. Officials in TB programs 
should monitor this indicator, review the use of regimens for special conditions, and follow-up 
with providers.
In pediatric TB patients, physicians may choose to withhold the use of EMB when the visual 
acuity of the patients cannot be monitored because EMB can cause optic neuritis. The graph 
below stratifies this indicator by age group to help programs monitor treatment in children 




Sputum Culture Result Reported
National Objective: For TB patients ages 12 years or older with a pleural or respiratory site of 
disease, increase the proportion who have a sputum culture result reported
Indicator
Percent of TB patients ages 12 years or older with a pleural or respiratory site of disease who 
have sputum culture result reported
CALCULATION
Percent (%) n/N x 100
Numerator (n) Number of TB patients with sputum culture results reported
Denominator (N) Number of TB patients ages 12 years or older with a pleural or 
respiratory (i.e., pulmonary and laryngeal) site of disease, alive at 




 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) fields:
 – 1 (Date Reported)
 – 8 (Date of Birth)
 – 15 (Status at TB Diagnosis)
 – 16 (Site of TB Disease)
 – 18 (Sputum Culture)
This indicator measures the extent to which the TB program or health care providers ensure that 
sputum specimen is collected and results reported for TB patients. 
Obtaining a sputum specimen is necessary to assess a patient’s level of infectiousness, identify 
the organism, test drug susceptibility, and obtain genotype results. Isolation of M. tuberculosis 
from children with pulmonary TB can be a challenge, which is why the working group 
recommended that the cohort for this objective be limited to TB patients ages 12 years or older. 
However, specimen collection from children for bacteriology is recommended by the American 
Throracic Society, the American Academy of Pediatrics, and CDC, without limitations for age.
“Sputum culture result reported” is defined as having either a positive or a negative sputum 
culture result reported to CDC. This specimen should have been collected within 2 weeks after 
the patient has initiated treatment. “Sputum culture result not reported” includes results that 
were not done, unknown, or missing. 
While sputum culture will not be needed for the diagnosis of tuberculosis and detection of drug-
resistance tuberculosis as the use of nucleic acid amplification test and rapid molecular test 
become more widely adopted, it will remain important and needed for obtaining genotype results. 
‘Reporting of Sputum Culture Results for TB Patients Ages 12 Years or Older with a Pleural or 






National objective: For TB patients with positive sputum culture results, increase the proportion 
who have documented conversion to negative results within 60 days of treatment initiation
Indicator
Percent of TB patients with positive sputum culture results who have documented conversion to 
negative results within 60 days of treatment initiation
CALCULATION
Percent (%) n/N x 100
Numerator (n) Number of TB patients who have documented conversion to negative 
results within 60 days of treatment initiation
Denominator (N) Number of TB patients with positive sputum culture results, alive at 
diagnosis, who have initiated treatment, counted in the cohort period 
of interest. Patients who died within 60 days of initiating treatment 
are excluded. For cohort 2009 onward, patients who moved out of the 




 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) fields:
 – 15 (Status at TB Diagnosis)
 – 18 (Sputum Culture)
 – 36 (Date Therapy Started) 
 – 37 (Initial Drug Regimen)
 – 41 (Sputum Culture Conversion Documented)
 ◆  Yes/No/Unknown
 ◆ Date specimen collected  
 – 42 (Moved)
 – 43 (Date Therapy Stopped)
 – 44 (Reason Therapy Stopped or Never Started) 
This indicator measures the extent to which sputum specimens are obtained promptly and 
culture conversion is documented. While conversion within 60 days is optimal, and documented 
conversion after 60 days is still acceptable, large numbers of cases with no such documentation 
suggests the need for improving procedures so that staff members understand the importance of 
documenting culture conversion. 
The completeness of this indicator is marked by the change of the purple bar graph to blue when 
the completeness of the variable, “Sputum Culture Conversion Documented” reaches 90% for 
the respective analytical cohort. 
The objective of monitoring culture conversion within 60 days has practical significance in the 
treatment of TB patients. While not all patients have conversion within 60 days, particularly 
those with cavitary disease and sputum smear-positive result, sputum collection and monitoring 
for culture conversion around the 60-day period is essential for assessing treatment progress and 
evaluating the effectiveness of a treatment regimen. 
According to the Treatment of Tuberculosis guidelines, approximately 80% of patients with pan-
susceptible pulmonary TB who had a positive sputum culture result before starting treatment will 
have a conversion to culture-negative after receiving 2 months of treatment. Refining treatment 
regimens, closely monitoring patients to ensure adherence, and extending treatment to a 
minimum of 9 months may be warranted for treatment success if conversion did not take place 
within 60 days of treatment initiation.
Sputum culture conversion is defined as 2 consecutive negative cultures with no positive cultures 
thereafter. The date of conversion is the specimen collection date for the first consistently 
negative culture. 
76
The Treatment of Tuberculosis guidelines recommend that sputum specimen collection for 
microscopic exams and culture be done monthly until two consecutive specimens have negative 
culture results, indicating successful culture conversion. Obtaining specimens and laboratory 
testing for assessing culture conversion can be costly. TB programs and health care providers 
need to balance between costs, and optimize return in investment, while striving for increased 
performance on this indicator. 
‘Sputum Culture Conversion for Patients with Positive Sputum Culture Results’ provides the data 
for TB programs to assess the proportion of cases with delayed or no documented conversion. 
(Quarterly report available)
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A stratification of this indicator by provider type is provided to help TB program managers focus 
further evaluation activities.
While most cases convert from a positive to a negative culture result within 60 days, research 
has found that patients with more severe forms of TB, particularly those with cavitary disease 
and AFB-positive sputum smears, take longer to convert. Using the graph, ‘Sputum Culture 
Conversion for Patients with Positive Sputum Culture Results, by Cavitary Disease and Positive 
Sputum Smear Result,’ TB program managers can monitor and assess the sputum culture 




In some instances, culture conversion was reported to have taken place before the date treatment 
was initiated. These cases are indicated by a negative number of days from treatment initiation 
to culture conversion on the line listed data for this indicator. While it is possible that patients 
with low bacterial load may have a subsequent negative culture result reported prior to starting 
treatment, laboratory contaminations or errors have been found among cases reported with a 
single positive culture result. TB program staff is encouraged to review cases with negative 
culture conversion days, in particular for cases recorded with a single positive culture, to ensure 
laboratory contamination or error is not the cause.
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Completion of Therapy (COT)
National objective: For patients with newly diagnosed TB disease for whom 12 months or less of 
treatment is indicated, increase the proportion who complete treatment within 12 months
Indicator
Percent of patients with newly diagnosed TB disease for whom treatment for 12 months or less is 
indicated who completed treatment within 12 months (366 days)
CALCULATION
Percent (%) n/N x 100
Numerator (n) Number of TB patients who complete treatment in less than or equal 
to 366 days
Denominator (N) Number of TB patients who are eligible1 to complete treatment within 
12 months, alive at diagnosis, and have started treatment. Patients 
who died within 366 days of initiating treatment are excluded. For 
cohort 2009 onward, patients who moved out of the country2 within 




1Conditions that require patients to have an extended course of treatment and thus not eligible to 
complete treatment within 12 months are excluded from this cohort. These conditions include
 ■ Meningeal TB
 ■ TB in the central nervous system
 ■ TB in bone or joint and the skeletal system 
 ■ Initial drug-susceptibility reported as resistant to rifampin
 ■ Cases in patients age 0–14 years with disseminated TB
• Disseminated TB is defined as –
 – Evidence of miliary TB on chest radiograph or chest CT scan, or 
 – A positive result from culture of blood specimen
 – A positive result of NAA testing from blood specimen
All other patients are included in this calculation (i.e., those with negative culture result, those 
with an unknown culture status, and those with positive culture result but unknown initial drug-
susceptibility test results).
2 Patients who moved outside of country within 366 days of initiating treatment are excluded for 
cases reported in 2009 onward.
Patients who moved out of the country are defined as those –
 ■ Reported as “Yes” on the question “Did the patient move during TB therapy?” in the RVCT 
data item “MOVED”
And 
 ■ Checked the box for “Out of the U.S.”
For cases in patients who moved out of the United States, “Reason Therapy Stopped” is reported 
as “Other.” The “Date Therapy Stopped” reflects the date medication was last ingested by the 
patient prior to moving, or the date the patient moved outside of the country.
Treatment outcome data (i.e., “Reason Therapy Stopped” and “Date Therapy Stopped”) for 
patients who moved outside of the country is updated when available. For these cases, the 
“Reason Therapy Stopped” may reflect “Completed” or “Died.” The “Date Therapy Stopped” 
reflects the actual date when treatment was completed or date the patient died.
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DATA SOURCES
 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) fields:
 – 1 (Date Report) 
 – 8 (Date of Birth)
 – 15 (Status at TB Diagnosis)
 – 16 (Site of TB Disease)
 – 20 (Culture of Tissue and Other Body Fluids)
 ◆ Anatomic code – Blood
 – 21 (Nucleic Acid AmplificationTest Result) 
 ◆ Anatomic code – Blood
 – 22 (Initial Chest Radiograph and Other Chest Imaging Study)
 – 36 (Date Therapy Started)
 – 37 (Initial Drug Regimen)
 – 40 (Initial Drug Susceptibility Results)
 – 42 (Moved)
 – 43 (Date Therapy Stopped)
 – 44 (Reason Therapy Stopped or Never Started) 
This indicator measures the degree to which TB patients complete therapy on time. The 
completeness of the indicator data is determined by the completeness of the variable “Date 
Therapy Stopped.”
Delays in completion of therapy can reflect treatment lapses and other undesirable outcomes 
such as default and loss to follow up. Most TB patients infected with a drug-susceptible  
M. tuberculosis strain should be able to complete treatment within 6 to 9 months. For drug 
resistance other than rifampin, TB patients are also expected to complete treatment within one 
year. The indicator, completion of treatment within 12 months, provides a 3 to 6 month grace 
period for the majority of TB patients. The following images from the Completion of Therapy 
Indicator Report illustrate the percentage of cases by treatment outcome and percentage of 
patients who completed treatment within 12 months by provider type and type of treatment 
supervision. 
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Beginning in 2009, cases in patients who moved out of the United States were excluded from 
calculation of the COT indicator. However, a graph is provided in this NTIP report to help 




Technical Note on Updates to COT calculation
2005:
1. Exclusion for meningeal disease was expanded from pediatric (age under 15 years) cases  
to all TB cases.
2. Exclusion for pediatric cases with bone or joint was dropped. 
2009: 
Reporting of miliary disease changed with RVCT Revision. 
Expired RVCT
Major Site of Disease: Miliary 
OR 
Additional Site of Disease: Miliary
Revised RVCT
Miliary TB is diagnosed through the reading of an ‘abnormal’ chest radiograph or 
chest CT scan.
 ■ Initial Chest Radiograph: Abnormal 
AND
Evidence of miliary TB: Yes 
 ■ Initial Chest CT Scan or Other Chest Imaging Study: Abnormal 
AND
Evidence of miliary TB: Yes
NOTE: For cases to be classified as miliary TB, the chest radiograph or chest CT scan must be 
reported as “Abnormal” and “Evidence of miliary TB” is reported as “Yes.”
2012:




Exclusion for cases of TB in bone or joint and the skeletal system and TB in the central nervous 
system. Modification of exclusions for died during therapy and moved out of the country to 
exclude only those patients who moved or died within one year of initiating treatment.
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VII. Monitoring Progress on Laboratory Reporting
This chapter covers indicators that are related to laboratory reporting.
Indicators for Laboratory Reporting
 ■ Laboratory Turnaround Time – Culture
 ■ Laboratory Turnaround Time – NAA
 ■ Drug-Susceptibility Result
 ■ Universal Genotyping
Data on laboratory results for TB cases are collected on the RVCT and reported to CDC 
through NTSS. All TB cases included in this set of indicators have been counted by reporting 
jurisdictions and meet the CDC TB surveillance definition and case verification criteria.
This set of indicators contributes to TB elimination by measuring key outputs from activities 
related to laboratory testing and reporting. Through rapid specimen processing and reporting of 
findings, laboratories contribute to the diagnosis and effective treatment of patients with active 
TB disease and the interruption of TB transmission. 
While TB programs may not have a direct role in laboratory activities measured in this set of 
indicators, they are direct beneficiaries of services and partners. Data related to TB cases are 
also extracted by TB program staff from laboratory reports and reported in RVCT to CDC. This set 
of indicators help TB program managers monitor laboratory activities, provide feedback, and work 
with laboratories to ensure information is received on time.
Resources
Treatment of Tuberculosis, MMWR 2003; 52 (No. RR-11)  
http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf
CDC Tuberculosis Surveillance Data Training, Report of Verified Case of Tuberculosis (RVCT): 
Instruction Manual, June 2009  
http://www.cdc.gov/tb/programs/rvct/InstructionManual.pdf
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Laboratory Turnaround Time – Culture
National Objective: For TB patients with cultures of respiratory specimens identified with  
M. tuberculosis complex (MTBC), increase the proportion reported by the laboratory within 25 
days from the date the specimen was collected
Indicator
Percent of TB patients who have the identification of MTBC from culture of respiratory 
specimens reported within 25 days from the date specimen was collected
NOTE: 25 days include 21 days for culture to grow and 4 days for specimen collection and 





Percent (%) n/N x 100
Numerator (n) Number of  TB patients who have the identification of MTBC from 
culture of respiratory specimens reported within 25 days from the date 
specimen was collected
Denominator (N) Number of TB patients with positive result for culture in respiratory 
specimens (i.e., sputum, upper respiratory fluids, tracheal fluid, and 
bronchial fluid), counted in the cohort period of interest. Patients 
with positive result for culture in non-respiratory specimen or gastric 
aspirate are excluded
NOTE: If two culture results are available, the respiratory specimen with the earliest report date 
will be assessed for this indicator.
DATA SOURCES 
 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) fields:
 – 5 (Count Status)
 – 6 (Date Counted)
 – 18 (Sputum Culture) 
 ◆ Result
 ◆ Date collected
 ◆ Date result reported
 – 20 (Culture of Tissue and Other Body Fluids) 
 ◆ Result
 ◆ Date collected
 ◆ Anatomic codes
◊ Upper respiratory fluids or tracheal fluid
◊ Bronchial fluid
 ◆ Date result reported
Prompt reporting of laboratory results for the confirmation of M. tuberculosis is important for 
clinical treatment decisions. Two methods commonly used to identify M. tuberculosis are  
1) liquid culture, and 2) nucleic acid amplification (NAA) test. The recommended laboratory 
turnaround time (TAT) for these two methods is different: 21 days for liquid culture and 2 days 
for NAA test. The TAT is the length of time from the date when the specimen is received at the 
laboratory to the date when the result is reported to the clinician.
Limited by the information known to the TB program staff and collected for surveillance,  
NTIP assesses the TAT based on the date specimen is collected and the date when the result  
is reported. Thus, 4 additional days is added to the indicator to allow for specimen delivery  
to laboratories.
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Laboratory Turnaround Time – NAA
National Objective: For TB patients with respiratory specimens positive for M. tuberculosis 
complex (MTBC) by nucleic acid amplification (NAA), increase the proportion reported by the 
laboratory within 6 days from the date the specimen was collected
Indicator
Percent of TB patients who have the detection of MTBC by NAA testing from respiratory 
specimens reported within 6 days from the date specimen was collected





Percent (%) n/N x 100
Numerator (n) Number of TB patients who have the detection of MTBC reported 
within 6 days from the date of specimen collection
Denominator (N) Number of TB patients with positive result for NAA test in respiratory 
specimens (i.e., sputum, upper respiratory fluids, tracheal fluid, and 
bronchial fluid), counted in the cohort period of interest. Patients with 
positive result for NAA test on non-respiratory specimen or gastric 
aspirate are excluded
DATA SOURCES 
 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) fields:
 – 5 (Count Status)
 – 6 (Date Counted)
 – 21 (Nucleic Acid Amplification Test Result)
 ◆ Result
 ◆ Date collected
 ◆ Anatomic codes
◊ Upper respiratory fluids or tracheal fluid
◊ Bronchial fluid
 ◆ Date result reported 
Prompt reporting of laboratory results for the confirmation of M. tuberculosis is important for 
clinical treatment decisions. Nucleic acid amplification (NAA) test is a rapid test, performed 
directly on patient specimens. The benefit of using NAA to detect M. tuberculosis complex 
is that it has a quick turnaround time (TAT). The recommended TAT for NAA test is 2 days, 
although the test results are often available immediately. The TAT is the length of time from the 
date when the specimen is received at the laboratory to the date when the result is reported to 
the clinician.
NTIP calculates laboratory TAT based on surveillance data collected in the RVCT, thus the 
TAT is  calculated based on the date specimen is collected and the date when the result is 
reported, instead of the date the laboratory received the specimen and the date when the result 
is reported. Four additional days is added to the indicator to allow for specimen delivery to 
laboratories.
Recent analysis suggests that often times NAA testing have been done on culture specimens, 
not direct patient specimens, which prolonged the TAT beyond that indicated for rapid testing, 





National objective: For TB patients with positive culture results, increase the proportion who have 
initial drug-susceptibility results reported
Indicator
Percent of TB patients with a positive culture result who have initial drug-susceptibility  
results reported
CALCULATION
Percent (%) n/N x 100
Numerator (n) Number of TB patients with initial drug-susceptibility results reported
Denominator (N) Number of TB patients with positive culture result, counted in the 




 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) fields:
 – 18 (Sputum Culture)
 – 20 (Culture of Tissue and Other Body Fluids)
 – 39 (Initial Drug Susceptibility Testing)
 – 40 (Initial Drug Susceptibility Results)
This indicator measures the proportion of TB patients with positive culture result for which drug 
susceptibility testing (DST) is done and reported. DST results are important in characterizing 
the organism and guiding TB treatment and treatment of contacts with newly-diagnosed latent 
TB infection. Failure to test for drug susceptibilities may lead to the use of less-than-optimum 
treatment regimens. 
The completeness of the indicator data is determined by the completeness of the variable “Initial 
Drug Susceptibility Testing.”
Drug susceptibility testing for INH, RIF, EMB, and PZA is recommended on the initial isolates 
of M. tuberculosis from all patients. However, because some public health laboratories do not 
have the capacity to perform PZA susceptibility testing, the calculation for this NTIP indicator 
currently includes DST testing for INH, RIF, and EMB only for cases reported after 2013. For 
cases reported prior to 2013, the calculation for this NTIP indicator includes DST for INH and 
RIF.
Inclusion of PZA in the calculation for DST will be implemented within the next few years. State 
TB program officials should work closely with their respective state public health laboratories to 
increase laboratory capacity to perform testing for PZA. 
TB program staff should also ensure that DST results are recorded and reported according to 
the RVCT. “Initial drug-susceptibility results reported” is defined as initial drug susceptibility 
results reported as “Yes” and the susceptibility results for INH, RIF, and EMB reported as either 
resistant or susceptible. 
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Universal Genotyping
National objective: For TB patients with a positive culture result, increase the proportion who 
have a MTBC genotyping result reported
Indicator
Percent of TB patients with a positive culture result who have an isolate submitted for genotyping 
and linked to the RVCT record
CALCULATION
Percentage (%) n/N x 100
Numerator (n) Number of TB patients with an isolate submitted for genotyping and 
linked to the RVCT record
Denominator (N) Number of TB patients with a positive culture result, counted in the  




 ■ National Tuberculosis Surveillance System (NTSS)
• Report of Verified Case of Tuberculosis (RVCT) fields:
 – 18 (Sputum Culture)
 – 20 (Culture of Tissue and Other Body Fluids)
 ■ National Tuberculosis Genotyping Information Management System (TB GIMS)
This indicator measures the proportion of culture-positive TB cases for which genotyping is done 
and reported. Genotyping results are important in guiding contact investigations and discovering 
or delineating TB outbreaks. 
An initial isolate should be submitted for genotyping by a CDC-funded genotyping laboratory, for 
all TB patients with positive culture results.
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VIII. Monitoring Progress on Contact Investigations
This chapter covers indicators that are related to investigations of contacts to smear-positive  
TB cases. 
Indicators for Contact Investigations
 ■ Contact Elicitation 
 ■ Examination
 ■ Treatment Initiation
 ■ Treatment Completion 
Data on contact investigations are collected and reported by TB programs to CDC via the 
Aggregate Reports for Tuberculosis Program Evaluation (ARPE) annually in September. 
Submissions of paper-based reports are then entered into NTIP by the DTBE ARPE Coordinator. 
TB program staff can also submit ARPE data to CDC electronically and update them through 
NTIP’s Electronic Data Submission for ARPE function on a real-time basis as data become 
available. Data submitted electronically are reflected in NTIP immediately. A step-by-step 
instruction guide on submitting ARPE data through NTIP is provided in the NTIP Companion for 
Data Managers. Contact Investigation reports are only available in the yearly trend.
While data on all contact investigations are documented and reported to CDC through ARPE, 
NTIP indicators focus on contacts to smear-positive TB cases, which are most likely to transmit 
TB. This set of indicators contributes to TB elimination by measuring the examination and follow-
up of contacts to highly infectious cases. By finding, evaluating, and treating contacts diagnosed 
with latent TB infection, TB programs contribute to decreasing TB incidence. Figure 4.1 outlines 
the activities, outputs, and the desired outcomes of TB prevention through contact tracing.
Resources
Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis: 
Recommendations from the National Tuberculosis Controllers Association and CDC 
MMWR 2005; 54 (No. RR-15, 1-37)  
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5415a1.htm
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection 
MMWR 2000; 49 (No. RR-6)  
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm
Latent Tuberculosis Infection: A Guide for Primary Health Care Providers 
http://www.cdc.gov/tb/publications/LTBI/treatment.htm





























































National objective: For TB patients with positive AFB sputum-smear results, increase the 
proportion who have contacts elicited
Indicator
Percent of sputum AFB smear-positive TB cases with contacts elicited
CALCULATION
Percent (%) n/N x 100
Numerator (n) Number of sputum AFB smear-positive TB cases with  
contacts elicited
Denominator (N) Number of sputum AFB smear-positive TB cases counted in  
the cohort period of interest
100
Sputum AFB smear-positive TB cases with contacts elicited is calculated by the number of 
sputum AFB smear-positive TB cases for investigation minus the number of sputum AFB smear-
positive TB cases with no contacts. 
DATA SOURCE
 ■ ARPE (Contacts) fields:
• Cohort Year
• a1 (Sputum smear+ Cases for Investigation)
• b1 (Sputum smear+ Cases with No Contacts)
This indicator measures the performance in finding at least one contact per sputum smear-
positive TB case and indirectly measures whether a contact investigation was initiated.
Contacts to sputum smear-positive cases are a high priority in contact investigations because 
of increased risk of transmission from smear-positive cases. Listing contacts is the first step of a 
contact investigation, followed by examination for infection and TB disease and treatment.
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Contact – Examination
National objective: For contacts to sputum AFB smear-positive TB cases, increase the proportion 
who are examined for infection and disease
Indicator
Percent of contacts to sputum AFB smear-positive TB cases examined for infection and disease
CALCULATION
Percent (%) n/N x 100
Numerator (n) Number of contacts to sputum AFB smear-positive  
TB cases examined
Denominator (N) Number of contacts to sputum AFB smear-positive TB cases  
counted in the year of interest
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DATA SOURCE: 
 ■ ARPE (Contacts) fields: 
• Cohort Year
• c1 (Number of Contacts to Sputum smear+ Cases)
• d1 (Contacts to Sputum smear+ Cases Evaluated)
This indicator measures the extent that contacts to sputum smear-positive cases are fully 
evaluated for TB infection and disease. Contacts to sputum smear-positive cases are a high 
priority in contact investigations because of the increased risk of transmission from smear-
positive cases.
Ensuring examination and treatment of high-risk contacts is important to prevent future TB 
cases. In addition, results of the medical examinations provide the basis for making overall 
decisions about contact investigation.
Contacts are counted as “examined” if they have been tested and examined to the point where 
a final determination of diagnosis is either latent TB infection, TB disease, or no infection or 
disease. A full medical examination among certain high-risk contacts may involve completion 
of chest X-ray or other examinations to rule out TB disease or infection, regardless of TST or 
interferon-gamma release assays (IGRA) test results.
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Contact – Treatment Initiation
National objective: For contacts to sputum AFB smear-positive TB cases diagnosed with latent 
TB infection (LTBI), increase the proportion who start treatment
Indicator
Percent of contacts to sputum AFB smear-positive TB cases diagnosed with LTBI who started 
treatment




Percent (%) n/N x 100
Numerator (n) Number of contacts started treatment
Denominator (N) Number of contacts to sputum AFB smear-positive TB cases diagnosed 
with LTBI, counted in the year of interest
DATA SOURCE
 ■ ARPE (Contacts) fields: 
• Cohort Year
• f1 (Contacts to Sputum smear+ Cases with Latent TB Infection)
• g1 (Contacts to Sputum smear+ Cases Diagnosed with Latent TB Infection Who 
Started Treatment)
This indicator measures the extent to which newly-infected contacts are started on an approved 
full-course treatment for LTBI. Although LTBI treatment is recommended for most infected 
contacts, newly-infected contacts to pulmonary cases are a priority for LTBI treatment because 
TB is most likely to develop in the first 1 to 2 years after a new infection. Treating contacts who 
have LTBI helps prevent future cases of TB.
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Contact – Treatment Completion
National objective: For contacts to sputum AFB smear-positive TB cases who have started 
treatment for latent TB infection (LTBI), increase the proportion who complete treatment
Indicator
Percent of contacts to sputum AFB smear-positive TB cases diagnosed with LTBI and started 
treatment who completed treatment 
CALCULATION
Percent (%) n/N x 100
Numerator (n) Number of contacts diagnosed with LTBI who completed treatment
Denominator (N) Number of contacts to sputum AFB smear-positive TB cases diagnosed 




 ■ ARPE (Contacts) fields: 
• Cohort Year
• g1 (Contacts to Sputum smear+ Cases Diagnosed with Latent TB Infection Who  
Started Treatment)
• h1 (Contacts to Sputum smear+ Cases Diagnosed with Latent TB Infection Who  
Completed Treatment)
This indicator measures the extent that newly-infected contacts to pulmonary cases starting a 
full-course of LTBI treatment complete this treatment. 
Although LTBI treatment is recommended for most infected contacts, newly-infected contacts 
to pulmonary cases are a priority for LTBI treatment because individuals are most likely to have 
active TB within the first 1-2 years of becoming infected. Contacts who complete treatment for 
LTBI are less likely to have TB disease than those who do not complete treatment. 
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Note: See ARPE Manual for definition and outcomes.
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IX. Monitoring Progress on Examination 
of Immigrants and Refugees
This chapter covers indicators that are related to the follow-up medical examination of 
immigrants and refugees arriving in the United States with TB Class B notification, specifically 
those with abnormal chest X-rays read overseas as suggestive of TB.
Data for this set of indicators derives from the Electronic Disease Notification (EDN) system.  
The system contains immigrant and refugee applicant medical data from the U.S. Department of 
State. EDN notifies state and local health departments of individuals with TB Class B notification 
arriving in their jurisdiction to facilitate follow-up. Data on the follow-up of these individuals are 
collected on the TB Follow-up Worksheet and submitted back to CDC through EDN.
This set of objectives contributes to TB elimination by monitoring the screening and completion 
of preventative treatment for tuberculosis among immigrants and refugees, who are considered 
a high risk group for TB disease. Through targeted testing and treatment of Class B immigrants 
and refugees, TB programs contribute to decreasing TB incidence among foreign-born persons. 
Figure 5.1, the logic model for the prevention of TB among high-risk populations, describes the 
activities, outputs, and the desired outcomes for the medical examination of this group.  
Indicators for Examination of Immigrants and Refugees
 ■ Examination Initiation
 ■ Examination Completion
 ■ Treatment Initiation
 ■ Treatment Completion 
Class B Notifications
Immigrants and refugees arriving in the United States are given classifications based on certain 
health conditions recorded during required pre-immigration medical examinations. These medical 
examinations are done by overseas panel physicians using technical instructions developed by 
the Division of Global Migration and Quarantine. Persons who are diagnosed with active TB are 
required to complete treatment prior to being approved to enter the United States. Persons who 
completed treatment for TB or who are noninfectious are given B classification and approval 
to enter the country. These classifications help immigration officers and public health officials 
prioritize individuals for follow-up medical examination after their arrival. For definitions and 
guidance, please refer to the Guidelines for Screening for Tuberculosis Infection and Disease 
during the Domestic Medical Examination for Newly Arrived Refugees.
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While immigrants and refugees may have class conditions designated for various health 
conditions requiring follow-up upon arrival in the United States, the national TB objectives 
or NTIP indicators focus on the medical follow-up examinations of persons with TB-related 
conditions, specifically those with abnormal chest X-rays read overseas as consistent with TB. 
These individuals may or may not include persons who are contacts to infectious TB patients or 
persons with latent TB infection. Individuals included in the analytical cohort of interest for NTIP 
are those with “abnormal finding” checked for chest X-rays and indicated to have conditions 
that are suggestive of tuberculosis on the Department of State Chest X-ray and Classification or 
Tuberculosis Worksheet.
For individuals examined using TB Technical Instruction (TI) 1991:
 ■ U.S. Department of State, Chest X-ray and Classification Worksheet DS-3024 published 
September 2007
• Chest X-ray Findings: Abnormal Findings 
 – Can suggest active TB
 – Can suggest inactive TB
For individuals examined using TB TI 2007:
 ■ U.S. Department of State, Chest X-ray and Classification Worksheet DS-3030 published 
July 2010
• Chest X-ray Findings: Abnormal Findings
 – Can suggest Tuberculosis
Or
 ■ U.S. Department of State, Tuberculosis Worksheet DS-3030 published September 2014
• Chest X-ray Findings: Abnormal Findings
 – Can suggest Tuberculosis
NOTE: NTIP indicators are calculated based on the primary jurisdiction of arrival. TB program 
managers can use EDN to electronically notify other jurisdictions of Class B individuals who 
move to another jurisdiction before completing their Class B examination and treatment. 
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Resources
Guidelines for Screening for Tuberculosis Infection and Disease during the Domestic Medical 
Examination for Newly Arrived Refugees  
http://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/tuberculosis-guidelines.html
Recommendations for Prevention and Control of Tuberculosis among Foreign-Born Persons, 
MMWR 1998; 47 (No. RR-16)   
http://www.cdc.gov/mmwr/preview/mmwrhtml/00054855.htm
TB Follow-up Worksheet Guide













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Immigrants and Refugees – Examination Initiation
National Objective: For immigrants and refugees with abnormal chest radiographs (X-rays) read 
overseas as consistent with TB, increase the proportion who initiate medical examination within 
30 days of notification
Indicator
Percent of immigrants and refugees with abnormal chest X-rays read overseas as consistent with 
TB who initiated medical examination within 30 days of notification
CALCULATION
Percent (%) n/N x 100
Numerator (n) Number of immigrants and refugees who initiated medical examination 
within 30 days of notification by EDN
Denominator (N) Number of immigrants and refugees with abnormal chest X-rays read 





 ■ Electronic Disease Notification (EDN) System 
• U.S. Department of State, Chest X-ray and Classification Worksheet
 – DS-3024 Form (published September 2007) field:
 ◆ Chest X-ray Findings
 – DS-3030 Form (published July 2010) field: 
 ◆ Chest X-ray Findings
• U.S. Department of State, Tuberculosis Worksheet
 – DS-3030 Form (published September 2014) field: 
 ◆ Chest X-ray Findings
• TB Follow-up Worksheet fields: 
 – A4 (Initial U.S. Entry Date)
 – C1 (Date of Initial U.S. Medical Evaluation)
• EDN system notification date
This indicator measures the extent that a follow-up medical examination of immigrants and 
refugees who arrived with a TB Class B notification is initiated within the recommended interval. 
Failure to initiate an examination shortly after arrival in the United States can lead to delayed 
diagnosis of active TB or to missed opportunities to diagnose and treat latent TB infection among 
foreign-born persons. 
The Date of Notification to the “primary jurisdiction of arrival” is used to determine the 
denominator of this indicator.
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Immigrants and Refugees – Examination Completion
National objective: For immigrants and refugees with abnormal chest X-rays read overseas as 
consistent with TB, increase the proportion who complete a medical examination within 90 days 
of notification
Indicator
Percent of immigrants and refugees with abnormal chest X-rays read overseas as consistent with 
TB who completed a medical examination within 90 days of notification
CALCULATION
Percent (%) n/N x 100
Numerator (n) Number of immigrants and refugees who completed medical 
examination within 90 days of notification by EDN
Denominator (N) Number of immigrants and refugees with abnormal chest X-rays  





 ■ Electronic Disease Notification (EDN) System
• U.S. Department of State, Chest X-ray and Classification Worksheet
 – DS-3024 Form (published September 2007) field:
 ◆ Chest X-ray Findings
 – DS-3030 Form (published July 2010) field: 
 ◆ Chest X-ray Findings
• U.S. Department of State, Tuberculosis Worksheet
 – DS-3030 Form (published September 2014) field: 
 ◆ Chest X-ray Findings
• TB Follow-up Worksheet fields:
 – A4 (Initial U.S. Entry Date)
 – D1 (Disposition Date)
 – D2 (Evaluation Disposition)
 ◆ Completed evaluation
 ◆ Treatment Recommended
 – D3 (Diagnosis)
• EDN system notification date
This indicator measures the extent that a follow-up medical examination of immigrants and 
refugees who arrived with a TB Class B notification is completed within the recommended 
interval.  Failure to complete an examination shortly after arrival in the United States can lead 
to delayed diagnosis of active TB or to missed opportunities to diagnose and treat latent TB 
infection among foreign-born persons. 
Examination Completed is defined as no missing information for whether treatment is 
recommended or not, and the diagnosis is not missing. The end points of domestic medical 
examination are indicated in D2. (i.e., Completed Evaluation, Initiated Evaluation/Not 
Completed, Did Not Initiate Evaluation). Once an examination end-point has been reached and  
a treatment recommendation has been made, the examination is considered to be completed. 
The objective is to reach a determination or disposition within 90 days after health department 
was notified of immigrants and refugees’ arrival. Once a disposition is reached, (if treatment is 
initiated or not) this data should be obtained by the appropriate jurisdiction and reported back to 
EDN promptly (See page 28 of TB Follow Up Guide).
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Note: The immigrants and refugees reported as having completed examination in this cohort 
includes those with incomplete responses on the ‘Evaluation Disposition Date,’ ‘Treatment 




Immigrants and Refugees – Treatment Initiation
National objective: For immigrants and refugees with abnormal chest X-rays read overseas as 
consistent with TB who are diagnosed with latent TB infection or have radiographic findings 
consistent with prior pulmonary TB (ATS/CDC Class 4) on the basis of examination in the U.S., 
for whom treatment was recommended, increase the proportion who start treatment
Indicator
Percent treatment initiation for immigrants and refugees with abnormal chest X-rays read 
overseas as consistent with TB who are diagnosed with latent TB infection (LTBI) or have 
radiographic findings consistent with prior pulmonary TB (ATS/CDC Class 4) and who are 
recommended for treatment on the basis of examination in the U.S.
CALCULATION
Percent (%) n/N x 100
Numerator (n) Number of immigrants and refugees who started treatment
Denominator (N) Number of immigrants and refugees with abnormal chest X-rays read 
overseas as consistent with TB who are diagnosed with LTBI or have 
radiographic findings consistent with prior pulmonary TB (ATS/CDC 
Class 4) and who are recommended for treatment on the basis of 




 ■ Electronic Disease Notification (EDN) System
• U.S. Department of State, Chest X-ray and Classification Worksheet
 – DS-3024 Form (published September 2007) field:
 ◆ Chest X-ray Findings
 – DS-3030 Form (published July 2010) field: 
 ◆ Chest X-ray Findings
• U.S. Department of State, Tuberculosis Worksheet
 – DS-3030 Form (published September 2014) field: 
 ◆ Chest X-ray Findings
• TB Follow-up Worksheet fields:
 – A4 (Initial U.S. Entry Date)
 – D2 (Evaluation Disposition)
 ◆ Completed Evaluation
 ◆ Treatment recommended
 – D3 (Diagnosis)
 – E1 (U.S. Treatment Initiated)
 – E2 (U.S. Treatment Start Date)
LTBI treatment helps prevent future cases of TB. This indicator measures the extent to which 
local TB programs ensure that immigrants and refugees diagnosed with LTBI or have radiographic 
findings consistent with prior pulmonary TB (ATS/CDC Class 4) on the basis of examination in the 
United States are started on treatment. 
According to the guidelines, all persons diagnosed with LTBI or have a radiographic finding 
consistent with prior pulmonary TB, who have not been treated for TB are recommended for LTBI 
treatment. Individuals with prior pulmonary TB (ATS/CDC Class 4) who have not been treated are 
at increased risk for progression to active disease. Other terminologies used when referring to 
prior pulmonary TB (ATS/CDC Class 4) include inactive TB disease, or old healed TB. Please refer 
to the guideline for Treatment of Tuberculosis for more information.
Under special circumstances, treatment may not be recommended for persons who are pregnant 
or have liver disease. Because these conditions are not captured in the TB Follow-up Worksheet, 
the NTIP Workgroup recommended that only individuals who are recorded as ‘Treatment 
Recommended’ be included in this indicator cohort.
TB program staff are encouraged to review records for individuals diagnosed with LTBI or who 
have radiographic findings consistent with prior pulmonary TB (ATS/CDC Class 4) for whom 
treatment was not recommended, to understand why treatment was not prescribed.
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Immigrants and Refugees – Treatment Completion
National objective: For immigrants and refugees with abnormal chest X-rays read overseas as 
consistent with TB who are diagnosed with latent TB infection or have radiographic findings 
consistent with prior pulmonary TB (ATS/CDC Class 4) on the basis of examination in the U.S., 
and who have started on treatment, increase the proportion who complete treatment
Indicator
Percent treatment completion for immigrants and refugees with abnormal chest X-rays read 
overseas as consistent with TB who are diagnosed with latent TB infection (LTBI) or have 
radiographic findings consistent with prior pulmonary TB (ATS/CDC Class 4) and recommended 
for treatment on the basis of examination in the U.S., who have started treatment
CALCULATION
Percent (%) n/N x 100
Numerator (n) Number of immigrants and refugees who completed treatment
Denominator (N) Number of immigrants and refugees with abnormal chest X-rays  
read overseas as consistent with TB who are diagnosed with LTBI 
or have radiographic findings consistent with prior pulmonary TB 
(ATS/CDC Class 4) and recommended for treatment on the basis of 





 ■ Electronic Disease Notification (EDN) System
• U.S. Department of State, Chest X-ray and Classification Worksheet
 – DS-3024 Form (published September 2007) field:
 ◆ Chest X-ray Findings
 – DS-3030 Form (published July 2010) field: 
 ◆ Chest X-ray Findings
• U.S. Department of State, Tuberculosis Worksheet
 – DS-3030 Form (published September 2014) field: 
 ◆ Chest X-ray Findings
• TB Follow-up Worksheet fields:
 – A4 (Initial U.S. Entry Date)
 – D2 (Evaluation Disposition)
 – D3 (Diagnosis)
 – E1 (U.S. Treatment Initiated)
 – E2 (U.S. Treatment Start Date)
 – E3 (U.S. Treatment Completed)
 – E4 (U.S. Treatment Completion Date or End Date)
This indicator measures the extent to which immigrants and refugees who are diagnosed with 
LTBI or have radiographic findings consistent with prior pulmonary TB (ATS/CDC Class 4) on the 
basis of U.S. examination and who started treatment complete treatment. Preventative treatment 






X. Evaluating Data Quality and Promptness
This chapter describes how surveillance data quality (i.e., accuracy, completeness and 
promptness) affects the data in NTIP indicator reports, and demonstrates how an user can use 
NTIP to assess surveillance data quality and delineate data problems.
Impact of Inaccurate or Incomplete Surveillance Data on  
NTIP Indicators
Inaccurate or incomplete surveillance data from the RVCT has tremendous impact on NTIP 
indicators. Missing or incorrect data in an RVCT variable used in an indicator calculation 
incorrectly classifies a TB case in the eligibility criteria for an indicator. A case may be 
incorrectly included or excluded from the denominator leading to inaccurate indicator results. 
Similarly, inaccurate or missing data in a variable for the numerator (used to determine whether a 
case met a particular objective) may lead to a lower than expected indicator result. 
Figure 6.1: Completion of Therapy Trend Graph with Missing Data
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Figure 6.1 provides an example from the Completion of Therapy objective. The figure illustrates 
how missing data in a variable, which determines whether cases met the objective, affect the 
indicator calculation. The NTIP graph indicates that none of the cases eligible to complete 
treatment within 12 months from 2008 to 2011 met the objective. The table accompanying 
the graph indicates that most of the patients have completed treatment, though none of the 
patients completed treatment within 12 months. This results in 0% treatment completion rate 
for this objective. Completion of Therapy indicator, two variables, the “Date Therapy Started” 
and “Date Therapy Stopped,” are used to calculate the treatment duration. While all completion 
of treatment is important, in order to meet the objective for this indicator treatment has to be 
completed within 366 days. Missing data in one key variable, such as “Date Therapy Stopped,” 
has a tremendous effect on the indicator result as shown in Figure 6.1. Figure 6.2 shows the 
graph after the missing variables are corrected.
Figure 6.2: Completion of Therapy Trend Graph without Missing Data
Using NTIP Graphs to Assess Surveillance Data Quality  
and Promptness
NTIP reports can be used to assess and monitor the quality of surveillance data submitted to 
CDC. Understanding how indicators are calculated, how data are presented, and the timing 
of surveillance data transmission to CDC, staff members from each TB program can use NTIP 
reports to assess the accuracy, completeness, and promptness of surveillance data and take the 
necessary action to ensure high quality surveillance data.
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Purple vs. Blue Bar Graph
The trend graph on each indicator report is a visual tool that provides clues on the accuracy, 
completeness, and promptness of surveillance data received by CDC. 
The color of the bar graph serves as an “indicator” of how complete surveillance data are for a 
particular cohort period. The color of the bar graph changes from purple to blue when the data 
are 90% complete (See Figure 6.3). For the Completion of Therapy indicator, the variable “Date 
Therapy Stopped” is used to determine data completeness. When the color of the graph turns 
blue, it signals that at least 90% of the patients in the reporting cohort period have a “Date 
Therapy Stopped.” When reviewing the indicator reports, noting the time period where the color 
of the bar graph remains purple gives a sense of the data completeness for the time-period. 
Figure 6.3: Completion of Therapy Trend Graph Illustrating Data Completeness  
A bar graph that remains purple in a time-period where most patients should have completed 
treatment, and therefore should have a stop therapy date, may indicate data quality issues.  
In Figure 6.4, the bar graphs for 2004 and 2005 data remained purple where the bar graphs  
for 2006 and 2007 have changed to blue suggesting possible data issues for the years 2004 
and 2005. 
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Figure 6.4: Completion of Therapy Trend Graph Illustrating Data Quality
Quarterly Trends
Utility of NTIP is in large part affected by on-time reporting to CDC.  The timing of reporting can 
be observed and monitored through NTIP. Understanding the timeline for case management, 
data collection, and reporting helps one interpret the graph for this purpose. Using Completion of 
Therapy as an example, the NTIP reports can be examined by quarters to assess the promptness 
of surveillance data reporting. For the Completion of Therapy indicator, eligible cases should 
complete treatment within 12 months. For example, most cases that were diagnosed with TB and 
counted in the fourth quarter of 2010 [2010-Q4] should have completed treatment by the 4th 
quarter of the following year [2011-Q4]. Because time is required for treatment completion data 
to be collected, reported to state TB programs, and transmitted to CDC, data may be delayed 
by the time they reach NTIP. Monitoring the completeness and promptness of surveillance data 
is in many ways similar to monitoring the progress of the individual program with respect to the 
indicator. From the perspective of evaluating a program that has kept their data collection and 
reporting in sync with their case management process, the cohort period that most cases would 
have completed treatment for the first quarter of 2012 is the 4th quarter 2010. The blue bar 
graph in Figure 6.5 and Figure 6.6 illustrate this point. In Figure 6.5, data for Completion of 
Therapy appears to be almost complete. The blue bars show that more than 90% of the data 
for Date Therapy Stopped is available for each quarter in 2010.  However, since there may be 
many patients still on therapy during 2011, the purple bars in Figure 6.6 show that the data for 
Date Therapy Stopped fall below 90%.  The height of the bars in the trend graph indicated that 
Completion of Therapy has suffered as well.  
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Figure 6.5: Completion of Therapy Trend Graph, by Quarter, 2009-Q4 to 2010-Q4
Figure 6.6: Completion of Therapy Trend Graph, by Quarter, 2010-Q4 to 2011-Q4
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In a program that has been transmitting data to CDC on a continuous basis as patients complete 
treatment, a curve reflecting the continued receipt of cases completing treatment within 12 
months can be observed (see Figure 6.7). In contrast, a program that has not been updating 
or transmitting data on a regular basis may be missing large amounts of data (see Figure 6.8). 
Delays in data reporting can also be observed when comparing programs’ indicator status to 
corresponding state or national averages. 
Figure 6.7: Completion of Therapy Trend Graph Illustrating Continuous Data Transmission
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Figure 6.8: Completion of Therapy Trend Graph Illustrating Delayed Data Transmission
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Line-Listed Data 
In assisting programs with data validation, NTIP provides line lists of cases that are summarized 
in the aggregate indicator reports. Program staff members can use the line list to help them find 
missing data in variables used to calculate the indicators that have contributed to cases being 
misclassified in the cohort eligibility criteria or for not meeting the indicator objective.  The 
screenshot below shows an example of a line list:
A Incomplete/Missing Data: Cells highlighted in purple are missing information for reason 
therapy stopped and duration of treatment.
B Treatment Duration > 366 Days: Cases with treatment duration over 366 days do not meet 
the objective for completing treatment within 1 year.  However, they may be included in the 
indicator cohort.
C Objective Met or Not Met: The cases (rows) highlighted in gray have been correctly 
classified as not meeting the completion of treatment objective (reason therapy stopped is not 
COMPLETED).  
D Tools: The ‘Sort & Filter’ and ‘Find & Select’ tools can be used to sort and filter the 




Appendix A: National TB Program Objectives and 
Performance Targets
Please refer to CDC website, http://www.cdc.gov/tb/programs/Evaluation/Indicators/
ProgramObjectives.pdf, for updates. 
Goals for Reducing TB Incidence 2020 Targets
TB Incidence Rate  
Reduce the incidence of TB disease.
1.4 cases  
per 100,000
U.S.-Born Persons  
Decrease the incidence of TB disease among U.S.-born persons.
0.4 cases  
per 100,000
Foreign-Born Persons  
Decrease the incidence of TB disease among foreign-born persons.
11.1 cases  
per 100,000
U.S.-Born Non-Hispanic Blacks or African Americans  
Decrease the incidence of TB disease among U.S.-born non-Hispanic  
blacks or African Americans.
1.5 cases  
per 100,000
Children Younger than 5 Years of Age  
Decrease the incidence of TB disease among children younger than 5 years of age.
0.3 cases  
per 100,000
Objectives on Case Management and Treatment 2020 Targets
Known HIV Status  
Increase the proportion of TB patients who have a positive or negative HIV test  
result reported.
98%
Treatment Initiation  
For TB patients with positive acid-fast bacillus (AFB) sputum-smear results, increase 
the proportion who initiated treatment within 7 days of specimen collection.
97%
Recommended Initial Therapy  
For patients whose diagnosis is likely to be TB disease, increase the proportion who 
are started on the recommended initial 4-drug regimen.
97%
Sputum Culture Result Reported  
For TB patients ages 12 years or older with a pleural or respiratory site of disease, 
increase the proportion who have a sputum culture result reported.
98%
Sputum Culture Conversion  
For TB patients with positive sputum culture results, increase the proportion who have 
documented conversion to negative results within 60 days of treatment initiation.
73%
Completion of Therapy 
For patients with newly diagnosed TB disease for whom 12 months or less of 




Objectives on Laboratory Reporting 2020 Targets
Turnaround Time — Culture  
For TB patients with cultures of respiratory specimens identified with M. tuberculosis 
complex (MTBC), increase the proportion reported by the laboratory within 25 days 
from the date the specimen was collected.
NOTE: 25 days includes 21 days for culture to grow and 4 days for specimen 
collection and delivery to lab. 
78%
Turnaround Time — Nucleic Acid Amplification (NAA)
For TB patients with respiratory specimens positive for MTBC by nucleic acid 
amplification (NAA), increase the proportion reported by the laboratory within 6 days 
from the date the specimen was collected.
NOTE: 6 days includes 2 days for detection and 4 days for specimen collection and 
delivery to lab.
92%
Drug-Susceptibility Result  
For TB patients with positive culture results, increase the proportion who have initial 
drug-susceptibility results reported.
100%
Universal Genotyping  
For TB patients with a positive culture result, increase the proportion who have a 
MTBC genotyping result reported.
100%
Objectives on Contact Investigations 2020 Targets
Contact Elicitation  




For contacts to sputum AFB smear-positive TB cases, increase the proportion who are 
examined for infection and disease.
93%
Treatment Initiation  
For contacts to sputum AFB smear-positive TB cases diagnosed with latent TB 
infection, increase the proportion who start treatment.
91%
Treatment Completion  
For contacts to sputum AFB smear-positive TB cases who have started treatment for 
latent TB infection, increase the proportion who complete treatment.
81%
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Objectives on Examination of Immigrants and Refugees 2020 Targets
Examination Initiation  
For immigrants and refugees with abnormal chest radiographs (X-rays) read overseas 
as consistent with TB, increase the proportion who initiate a medical examination 
within 30 days of notification.
84%
Examination Completion  
For immigrants and refugees with abnormal chest X-rays read overseas as consistent 
with TB, increase the proportion who complete a medical examination within 90 days 
of notification.
76%
Treatment Initiation  
For immigrants and refugees with abnormal chest X-rays read overseas as consistent 
with TB who are diagnosed with latent TB infection or have radiographic findings 
consistent with prior pulmonary TB (ATS/CDC Class 4) on the basis of examination  




For immigrants and refugees with abnormal chest X-rays read overseas as consistent 
with TB who are diagnosed with latent TB infection or have radiographic findings 
consistent with prior pulmonary TB (ATS/CDC Class 4) on the basis of examination 
in the U.S. and recommended for treatment, and who have started on treatment, 
increase the proportion who complete treatment.
98%
Objectives on Data Reporting 2020 Targets
RVCT  
Ensure the completeness of each core Report of Verified Case of Tuberculosis 




Ensure the completeness of each core Aggregate Reports for Tuberculosis Program 




Ensure the completeness of each core Electronic Disease Notification (EDN) 




Objectives on Program Evaluation
Evaluation Activities  
Increase program evaluation activities by monitoring program progress and tracking  
evaluation status of TB cooperative agreement recipients.
Evaluation Focal Point  
Increase the percent of TB cooperative agreement recipients that have an evaluation  
focal point.
Objectives on Human Resource Development
Development Plan  
Increase the percent of TB cooperative agreement recipients who submit a program-specific 
human resource development plan (HRD) and a yearly update of progress, as outlined in the 
TB cooperative agreement announcement.
Training Focal Point  




For a complete list of terms and definitions, please refer to CDC Tuberculosis Surveillance  




Microorganisms that when stained, retain color even after they have 
been washed in an acid alcohol solution; may be detected under a 
microscope in stained smear.
Active TB disease
An illness, caused by bacteria called Mycobacterium tuberculosis, 
in which tuberculosis (TB) bacteria are multiplying and attacking 
parts of the body, most commonly the lungs. A person with active TB 
disease is capable of spreading the disease to others if the TB bacteria 
are active in the lungs or throat. The symptoms of active TB disease 
include weakness, weight loss, fever, no appetite, chills, and night 
sweats. Other symptoms may include a bad cough, pain in the chest, 
and coughing up blood. 
Adherence to treatment Following the recommended course of treatment by taking all the 
prescribed medications for the entire length of time necessary.
Adverse effect Negative side effect resulting from the use of a drug (for example, 
hepatitis, nausea, headache).
Aggregate Reports for 
Tuberculosis Program 
Evaluation (ARPE) - 
Contacts
A national summary report tool that helps evaluate non-case finding 
and non-case holding TB prevention activities. These prevention 
activities include contact tracing, targeted testing, and treating latent 
tuberculosis infection. 
Bronchoscopy A procedure used to obtain pulmonary secretions or lung tissue with 
an instrument called a bronchoscope.
Case management
A system in which a specific health department employee is assigned 
primary responsibility for the patient, systematic regular review of 
patient progress is conducted, and plans are made to address any 
barriers to adherence.
Incidence rate
The number of cases that occur during a certain time period, divided 
by the size of the population during that time period; the incidence 
rate is often expressed in terms of a population size of 100,000 
persons.
Case reporting Informing the state or local health department when a new case (an 
occurrence) of TB disease has been diagnosed or is suspected.
Cavity A hollow space within the lung, visible on a chest X-ray or CT scan.
Contact investigation
A procedure for interviewing a person who has TB disease to 
determine who may have been exposed to TB. People who have 





Persons who were exposed to someone with infectious TB disease, 
generally including family members, roommates or housemates, close 
friends, coworkers, classmates, and others.
Country of birth The country where a person was born.
Culture To grow organisms on media (substances containing nutrients) so that 
the micro-oorganisms or the product of this process can be identified.
Daily regimen A treatment schedule in which the patient takes a dose of each 
prescribed medication every day.
Diagnostic evaluation
An evaluation used to diagnose TB disease: includes a medical 
history, a chest X-ray, the collection of specimens for bacteriologic 
examination, and possibly a tuberculin skin test or an interferon-
gamma release assay such as the QuantiFERON®-TB Gold test.
Directly observed therapy 
(DOT)
A designated person watches the TB patient swallow each dose of the 
prescribed drugs.
Drug susceptibility test A laboratory method for finding drug resistance in a microorganism. 
Drug-resistant TB
TB caused by organisms that are able to grow in the presence 





A system that notifies state and local public health officials of 
immigrant and refugee arrivals into their jurisdiction who have 
been found to have suspected TB during their overseas medical 
examination.
Ethambutol (EMB)
A drug used to treat TB disease; may cause vision problems. 
Ethambutol should be used cautiously in children who are too young 
to be monitored for changes in their vision.
Extrapulmonary TB
TB disease that occurs in places other than the lungs, such as the 
lymph nodes, the pleura, the brain, the kidneys, or the bones; most 
types of extrapulmonary TB are not infectious.
First-line TB drugs The initial drugs used for treating TB disease.  Includes isoniazid 
(INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB). 
Foreign-born persons People born outside of the United States.
HIV Human immunodeficiency virus: the virus that causes AIDS.
Isolate A sample from a specimen that was identified as a certain organism 
such as M. tuberculosis complex.
Isoniazid (INH) A drug that is used for treating LTBI and one of the drugs used to treat 
TB disease.
Latent TB infection 
(LTBI)
Refers to the condition when a person is infected with tubercle bacilli, 
but TB disease has not developed. Persons with LTBI do not have 
TB disease symptoms and they cannot spread TB germs to others. 
Persons with LTBI usually have a positive result to the Mantoux 
tuberculin skin test or an interferon-gamma release assay.
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Term Definition
LTBI treatment Medication that is given to people who have latent TB infection to 
prevent them from developing TB disease.
Mantoux tuberculin skin 
test (TST)
A method of testing for TB infection; a needle and syringe are used to 
inject 0.1 ml of 5 tuberculin units of tuberculin solution between the 
layers of the skin (intradermally), usually on the forearm, the reaction 
to this test, a palpable swollen area (induration), is measured 48 to 
72 hours after the injection and is interpreted as positive or negative 
depending on the size of the reaction and the patient’s risk factors for 
TB.
Miliary TB
Miliary TB is a serious type of tuberculosis disease. It is a histological 
or radiologic finding, rather than a site of disease. It appears on 
radiograph as a great number of small, well-defined nodules that look 




TB disease resistant to at least the drugs isoniazid and rifampin: MDR 
TB is more difficult to treat than drug-susceptible TB.
Mycobacterium 
tuberculosis complex
A group of closely related mycobacteria that cause active TB (e.g., 
M. tuberculosis, M. bovis, and M. africanum). Most TB in the United 




The National TB Surveillance System collects information on each 
newly reported case of tuberculosis (TB) disease in the U.S. The 




A technique that amplifies (copies) DNA or RNA segments, in order to 
directly detect microorganisms in patient specimens.
Pyrazinamide (PZA) A drug used to treat TB disease.
Pulmonary TB
TB disease that occurs in the lungs, typically causing a cough and an 
abnormal chest X-ray. Most TB cases reported in the United States are 
pulmonary TB.
Report of Verified Case 
of Tuberculosis (RVCT)
The national tuberculosis surveillance data reporting form. All 
jurisdictions report these data to CDC on each newly reported case of 
TB. The results are used for determining the TB morbidity incidence 
rates for the United States, U.S. Territories, and Affiliated Islands.
Rifabutin A drug used to treat TB disease.
Rifampin A drug used to treat TB disease; also used for LTBI treatment. 
Rifapentine A drug used to treat TB disease.
Smear
A specimen that has been smeared onto a glass slide, stained, washed 
in an acid alcohol solution, and then placed under the microscope for 
examination: used to detect acid-fast bacilli in a specimen.
Specimen A sample collected from a person for testing.




Susceptibility An micro-organism’s ability to be killed by a particular drug.
Suspect
A patient for whom there is a high index of suspicion for active TB 
(e.g., a known contact to an active TB case or to a person with signs or 
symptoms consistent with TB) who is currently under evaluation for TB 
disease.
TB cases Instances where patients have been diagnosed with TB disease.
TB Follow-up Worksheet A worksheet used to document the medical examination of an 
immigrant or refugee arrived in the U.S. with a TB Class Condition. 
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